Skip to main content

Fluticasone News

Related terms: Fluticasone Topical, Fluticasone Nasal

Xhance Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

YARDLEY, Pa., March 15, 2024 (GLOBE NEWSWIRE) – Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...

Fluticasone Furoate Does Not Cut Time to COVID-19 Symptom Resolution

THURSDAY, Sept. 21, 2023 – For outpatients with mild-to-moderate COVID-19, inhaled fluticasone furoate does not shorten time to symptom resolution, according to a study published in the Sept. 21...

GSK Receives FDA Approval of Arnuity Ellipta for Asthma in Children From 5 Years of Age

London, UK 21 May 2018 --GSK today announced it has received approval from the US Food and Drug Administration (FDA) for the use of Arnuity Ellipta (fluticasone furoate) a once-daily inhaled...

Optinose Announces FDA Approval of Xhance (fluticasone propionate) Nasal Spray for the Treatment of Nasal Polyps

YARDLEY, Pa.--(BUSINESS WIRE)-- September 18, 2017 – Optinose, an ENT / Allergy specialty pharmaceutical company, announced today that the U.S. Food & Drug Administration (FDA) approved the...

FDA Approves Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for the Treatment of COPD

London UK – 18 September 2017 – GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved once-daily, single i...

Teva Announces FDA Approval of ArmonAir RespiClick (fluticasone propionate) for Maintenance Treatment of Asthma

JERUSALEM--(BUSINESS WIRE) January 30, 2017 --Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved ArmonAir...

FDA Approves Flonase Sensimist Allergy Relief

WARREN, N.J. 2 August 2016 – GSK Consumer Healthcare announced today that the U.S. Food and Drug Administration (FDA) has approved Flonase® Sensimist™ Allergy Relief (fluticasone furoate, 27.5 mcg sp...

FDA Approves Arnuity Ellipta (fluticasone furoate) for the Treatment of Asthma

20 August 2014 – GlaxoSmithKline plc today announced that the Food and Drug Administration has approved Arnuity Ellipta (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid...

FDA Approves Flonase Allergy Relief for Sale Over-the-Counter in the United States

London UK & Parsippany, US - Thursday 24 July 2014, GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the U.S. Food and Drug Administration (FDA) has approved Flonase Allergy Relief...

FDA Approves Breo Ellipta to Treat Chronic Obstructive Pulmonary Disease (COPD)

May 10, 2013 – The U.S. Food and Drug Administration today approved Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for the long-term, once-daily, maintenance treatment of...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Asthma - Maintenance, Asthma

Fluticasone patient information at Drugs.com